Compare Nomura Holdings Inc (NMR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Natera Inc. Common Stock — how do they compare? Nomura Holdings Inc trades at $9.2 (market cap $28.01B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays a 3.38% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 56 Days and Natera Inc. Common Stock for 0 Days on average.
| NMR | NTRA | |
|---|---|---|
Market Cap | $28.01B | $57.03B |
Volume | 686,801 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $10.86 | $425.64 |
52-Week Low | $6.92 | $179.42 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $38.48T | $56.18B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.26, down 3.24% with bearish technical signals. The stock shows mixed earnings performance with recent misses but strong revenue growth from $1.66T in 2025. Valuation appears attractive with P/E of 11.37 and P/B of 1.16, while analyst sentiment leans cautious with 67% hold ratings. Recent Zacks coverage highlights momentum potential and hammer chart pattern formation.
Outlook remains balanced with fundamental strength in profitability margins (20.4% net income) offset by technical weakness. Investment opportunity lies in discounted valuation amid earnings growth, while risks include cash flow volatility and rising debt levels. The stock requires careful monitoring of Q3 2026 earnings results for directional clarity.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
